Shares of UK-based Verona Pharma plc (VRNA) soared nearly 45% on Thursday and added another 23% in extended trading as the Company awaits data from its phase IIb dose-ranging study evaluating the effect of nebulized Ensifentrine as an add-on to treatment with a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease.
from RTT - Biotech https://ift.tt/2Q1Pzgs
via IFTTT
No comments:
Post a Comment